Recor Medical Gains AMA CPT Codes for Renal Denervation Procedure
Recor Medical's Paradise ultrasound renal denervation system received two new Category I CPT codes from the AMA, enabling standardized billing and potentially expanding patient access for uncontrolled hypertension treatment.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
The AMA CPT Editorial Panel approved two new Category I CPT codes for Recor Medical's Paradise ultrasound renal denervation system. Category I codes represent procedures with established clinical utility and peer-reviewed evidence.
Why it matters
Category I CPT codes enable standardized procedure reporting and billing across healthcare systems. This removes a reimbursement friction point and signals regulatory/clinical acceptance, likely improving payer coverage decisions and physician adoption rates for the Paradise system in the hypertension treatment market.
Market transmission
First-order: improved billing clarity and payer reimbursement pathways reduce adoption barriers for Recor's device. Second-order: broader clinical adoption increases procedure volume, supporting revenue growth and market share in the renal denervation space; positive signal may also influence competitive positioning against other denervation platforms.
What to watch
Monitor payer coverage decisions (Medicare, major insurers) following CPT code approval; track Recor procedure volume and revenue guidance in upcoming earnings; watch for competitive responses from other renal denervation device makers (e.g., Medtronic, Boston Scientific).
Sources:GlobeNewswire USGlobeNewswire France
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.